Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
APLT 
Applied Therapeutics Inc (APLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: APLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.48% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.07M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 2249906 | Beta 1.88 | 52 Weeks Range 0.43 - 10.62 | Updated Date 03/30/2025 |
52 Weeks Range 0.43 - 10.62 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-04 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -24379.51% |
Management Effectiveness
Return on Assets (TTM) -76.01% | Return on Equity (TTM) -473.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -36821153 | Price to Sales(TTM) 54.68 |
Enterprise Value -36821153 | Price to Sales(TTM) 54.68 | ||
Enterprise Value to Revenue 62.37 | Enterprise Value to EBITDA -9.71 | Shares Outstanding 116356000 | Shares Floating 71780309 |
Shares Outstanding 116356000 | Shares Floating 71780309 | ||
Percent Insiders 6.47 | Percent Institutions 107.37 |
Analyst Ratings
Rating 4 | Target Price 5.92 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Applied Therapeutics Inc
Company Overview
History and Background
Applied Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for underserved diseases, particularly those with significant unmet medical needs. Founded in 2016, the company has rapidly advanced a pipeline of clinical and preclinical programs.
Core Business Areas
- Neurology: Development of therapeutics for central nervous system disorders, including SORD deficiency and other neurological diseases.
- Cardiology: Development of therapeutics for diabetic cardiomyopathy (DbCM) and other cardiovascular diseases.
Leadership and Structure
Dr. Shoshana Shendelman is the founder, CEO, and President. The company has a management team with expertise in drug development and commercialization. Operates with a typical biopharmaceutical company structure, including research, clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Govorestat (AT-007): An investigational Aldose Reductase Inhibitor (ARI) for SORD deficiency. There is no approved treatment for SORD deficiency, representing a potentially significant market. Competitors include companies developing gene therapies or other novel approaches for rare genetic disorders.
- AT-0019: An investigational drug for Diabetic Cardiomyopathy (DbCM). Competitors include companies developing therapies targeting cardiovascular disease, such as Eli Lilly (LLY) and Boehringer Ingelheim (privately held).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and significant competition. The focus is on developing novel therapeutics for unmet medical needs. The market is driven by aging populations, increasing prevalence of chronic diseases, and advancements in drug discovery technologies.
Positioning
Applied Therapeutics is positioned as a developer of novel therapeutics for rare and underserved diseases, targeting specific metabolic pathways. Its competitive advantage lies in its proprietary drug candidates and its focus on diseases with limited treatment options.
Total Addressable Market (TAM)
The total addressable market varies significantly based on the specific disease target (SORD, DbCM etc). SORD deficiency affects a small number of patients, leading to smaller markets compared to DbCM, which affects millions of people worldwide. The DbCM market is estimated to be in the billions. Applied Therapeutics is positioned to capture a significant share of niche markets if their treatments gain regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet medical needs
- Strong intellectual property portfolio
- Experienced management team
- Focus on orphan diseases
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Dependence on regulatory approvals
- Limited commercialization experience
Opportunities
- Potential for breakthrough therapies
- Expansion into new therapeutic areas
- Partnerships and collaborations with larger pharmaceutical companies
- Favorable regulatory environment for orphan drugs
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Funding risks
Competitors and Market Share
Key Competitors
- LLY
- GILD
- VRTX
Competitive Landscape
APLT competes in a market dominated by larger pharmaceutical companies. Its strength lies in its focus on niche markets and novel drug candidates. However, it faces challenges related to funding and commercialization.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by clinical development milestones and investor sentiment. As a relatively new company, it is still in the early stages of growth.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates vary based on the perceived likelihood of success. Positive clinical data would likely lead to increased analyst target prices.
Recent Initiatives: Focus on advancing clinical trials for Govorestat and AT-0019. Seeking partnerships to support commercialization.
Summary
Applied Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases with unmet needs. The company's success hinges on the successful completion of ongoing clinical trials and securing regulatory approvals. Despite having promising drug candidates, the company faces substantial risks related to clinical development, regulatory approvals, and funding. Its future depends on positive trial outcomes and effective management of resources.
Similar Companies
- CRSP
- BEAM
- EDIT
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data is based on available information and may be subject to change. Investing in biopharmaceutical companies involves significant risks, including the risk of losing your entire investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Applied Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-05-14 | Interm CEO, CFO, Principal Financial Officer & Director Mr. Les D. Funtleyder | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | |
Full time employees 37 | |||
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.